Omega-3 fatty acids in canine heart failure and ventricular arrhythmias — POSSIBLE

In dogs with congestive heart failure or breed-associated ventricular arrhythmias, does fish-oil (omega-3) supplementation vs placebo improve cardiac cachexia measures or reduce arrhythmia frequency?

Shelf #216 · gate-verified and approved by the developer

POSSIBLE: Fish oil shows real but narrow effects in two small, short, placebo-controlled canine trials, on two different endpoints. In 24 Boxers with arrhythmogenic right ventricular cardiomyopathy, 6 weeks of fish oil (2 g) reduced 24-hour ventricular premature contractions within the fish-oil group (median 397 to 162; P = .02), while flax oil and sunflower-oil control groups did not change significantly — but the abstract reports no between-group comparison, so the claim rests on a within-group change in a handful of dogs. In 28 dogs with heart failure, 8 weeks of fish oil decreased interleukin-1 beta (P = .02) and improved cachexia versus placebo (P = .01). Neither trial measured survival or clinical events, and neither was large or long; the stamp is POSSIBLE, and no life-prolonging claim is made. Drafted Nov 10, 2026 (VetMed build, topic #216); all figures from abstracts fetched and verified at drafting.

Smith 2007: fish oil cut Boxer VPCs within-group (median 397 → 162 per 24 h; P = .02); flax and control oils did not

Randomized, blinded, oil-controlled trial (record's own abstract wording: dogs 'randomized to 1 of 3 treatments'; 'Investigators and owners were blinded to the treatment groups'; indexed as Clinical Trial)

Who: Dogs: 24 Boxer dogs with arrhythmogenic right ventricular cardiomyopathy, asymptomatic and not receiving antiarrhythmic medications. Dogs with > 95 ventricular premature contractions (VPCs) in 24 hours on ambulatory electrocardiography were randomized to one of three treatments for 6 weeks: fish oil 2 g, flax oil 2 g, or sunflower oil 2 g (control group). Investigators and owners were blinded to the treatment groups. All baseline measurements were repeated after the 6-week supplementation.

Result: There were no differences at baseline for age, sex, blood pressure, weight, echocardiographic measurements, or VPCs. The median number of VPCs in 24 hours for all dogs was 543 (range, 96–40,063) at baseline and 193 (range, 6–14,825) after 6 weeks of supplementation. VPCs/24 h were reduced for the fish oil group (baseline median = 397 [range, 249–10,587]; 6-week median = 162 [range, 16–3,781]; P = .02), but not for the flax oil (P = .58) or control (P = .48) groups. The authors concluded that fish oil, but not flax oil, supplementation for 6 weeks reduces arrhythmia in Boxers with ARVC, and that further studies are needed to determine optimal dose and duration.

Watch out: The significant P value is a within-group change in the fish-oil arm; the abstract reports no between-group statistical comparison, and with 24 dogs split across three arms each group is very small. VPC count is a surrogate endpoint — the trial measured no survival, syncope, or quality-of-life outcome, and ran only 6 weeks. The control was sunflower oil, an active oil comparator, not an inert placebo capsule.

Smith CE, Freeman LM, Rush JE, Cunningham SM, Biourge V. Omega-3 fatty acids in Boxer dogs with arrhythmogenic right ventricular cardiomyopathy. J Vet Intern Med. 2007;21(2):265-73. PMID: 17427387. Registry ID: none in the record. MeSH: Animal Feed · Animal Nutritional Physiological Phenomena · Animals · Arrhythmias, Cardiac · Diet · Dietary Supplements · Dog Diseases · Dogs · Fatty Acids, Omega-3 · Ventricular Dysfunction, Right

Freeman 1998: fish oil lowered IL-1 beta (P = .02) and improved cachexia (P = .01) vs placebo in dogs with heart failure

Randomized, placebo-controlled trial (record's own abstract wording: dogs 'randomized to receive either fish oil or placebo'; indexed as Randomized Controlled Trial)

Who: Dogs: 28 dogs with heart failure (with 5 healthy controls used for baseline comparisons of body composition, fatty acids and cytokines). Dogs with heart failure were then randomized to receive either fish oil or placebo for 8 weeks, with all parameters measured again at the end of the study period. At baseline, 54% of dogs with heart failure were cachectic.

Result: At baseline, the severity of cachexia correlated with circulating tumor necrosis factor-alpha concentrations (P = .05), although cytokine concentrations were not significantly increased in dogs with heart failure compared with controls; baseline plasma arachidonic acid (P = .02), eicosapentaenoic acid (P = .03), and docosahexaenoic acid (P = .004) concentrations were lower in dogs with heart failure than in controls. Fish oil supplementation decreased interleukin-1 beta (IL-1) concentrations (P = .02) and improved cachexia (P = .01) compared with the placebo group. The mean caloric intake of the heart failure dogs as a group was below the maintenance energy requirement (P < .001), but no difference was found in food intake between the fish oil and placebo groups. Insulin-like growth factor-1 concentrations (P = .01) and reductions in circulating IL-1 concentrations over the study period (P = .02) correlated with survival.

Watch out: Blinding is not stated anywhere in this record — randomisation and placebo control are established, blinding is not. The survival findings are correlations (IGF-1 and IL-1 change tracked with survival), not a randomised survival benefit of fish oil; do not quote them as one. Small (28 heart-failure dogs), 8 weeks, and the endpoints are cachexia and cytokine measures, not clinical events.

Freeman LM, Rush JE, Kehayias JJ et al. Nutritional alterations and the effect of fish oil supplementation in dogs with heart failure. J Vet Intern Med. 1998;12(6):440-8. PMID: 9857337. Registry ID: none in the record. MeSH: Animals · Body Composition · Body Water · Cachexia · Chromatography, Gas · Dinoprostone · Dog Diseases · Dogs · Eating · Fatty Acids · Fish Oils · Gas Chromatography-Mass Spectrometry · Heart Diseases · Insulin-Like Growth Factor I · Interleukin-1 · Nutritional Status · Reference Values · Tumor Necrosis Factor-alpha

Synthesis: two small trials, two surrogate endpoints — a real signal, not a proven treatment

Synthesis

Who: Synthesis of the two cards above: Smith et al. 2007 (24 Boxers with ARVC, fish vs flax vs sunflower oil, 6 weeks, blinded) and Freeman et al. 1998 (28 dogs with heart failure, fish oil vs placebo, 8 weeks, randomised).

Result: The two trials point the same general direction — fish oil did something measurable that its comparators did not — but they answer different questions in different populations with surrogate endpoints: fewer ventricular premature contractions in Boxers (within-group significance only) and less cachexia with lower IL-1 beta in heart-failure dogs. Together they justify POSSIBLE for fish oil as a modest adjunct in these specific settings. They do not show longer life, fewer cardiac events, or benefit in other breeds, other heart diseases, or at other doses, and the shelf makes none of those claims.

Watch out: The Freeman 1998 trial's fish-oil dose is not given in its abstract record, and the Smith 2007 dose (2 g) was in Boxers with one specific disease — neither record supports a general dosing recommendation for cardiac patients.

Synthesis of Smith CE et al. PMID: 17427387 and Freeman LM et al. PMID: 9857337. Registry IDs as on the individual cards.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.